CardioFocus
12
2
3
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
16.7%
2 terminated/withdrawn out of 12 trials
77.8%
-8.8% vs industry average
50%
6 trials in Phase 3/4
86%
6 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
Ablation With the PFA System With a Large-Area Focal Catheter for the Treatment of Persistent Atrial Fibrillation
Role: lead
Pulmonary Vein Isolation With the Single Shot Endoscopic Ultra-Compliant PFA Balloon for the Treatment of AF
Role: lead
CardioFocus HeartLight Post-Approval Study
Role: lead
HeartLight X3 Endoscopic Ablation System With Excalibur Balloon for Treatment of Symptomatic Persistent AF
Role: lead
Clinical Study of the HeartLight X3 Endoscopic Ablation System With Excalibur Balloon
Role: lead
Laser Ablation Study for trEatment of atRial Fibrillation (LASER)
Role: collaborator
HeartLight Ablation in Patients With Paroxysmal Atrial Fibrillation (PAF)
Role: lead
Clinical Study of the CardioFocus Endoscopic Ablation System for the Treatment of Symptomatic AF
Role: lead
Post-Market Randomized Trial: Endoscopically- Guided Ablation vs. Radiofrequency Ablation
Role: lead
Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation
Role: lead
Post-Market Clinical Study of the CardioFocus Endoscopic Ablation System - Adaptive Contact (CF-EAS-AC) for the Treatment of Symptomatic Atrial Fibrillation
Role: lead
Pivotal Clinical Study of Endoscopic Ablation for Atrial Fibrillation (AF) in Patients That Have Failed Drugs
Role: lead
All 12 trials loaded